Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients

Recipients after hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor T-cell (CAR-T) therapy are at increased risk for unfavorable outcomes after SARS-CoV-2 infection. The efficacy of COVID-19 vaccines remains undetermined in this vulnerable population, we therefore conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xi, Wang, Lu, Shen, Lu, He, Lin, Tang, Kefu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200932/
https://www.ncbi.nlm.nih.gov/pubmed/35710431
http://dx.doi.org/10.1186/s13045-022-01300-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200932/
https://www.ncbi.nlm.nih.gov/pubmed/35710431
http://dx.doi.org/10.1186/s13045-022-01300-9

Ejemplares similares